

Personal Information



Sirikul Sorrarittichingchai

Address: Lampang Cancer Hospital

Country: Thailand

Curriculum Vitae

Education : Year / degree / Institution

| | | |
|-----------|-----------------------------|---|
| 1994 | Doctor of Medicine(M.D.) | Chiangmai University, Chiangmai, Thailand |
| 1998-2000 | Internal Medicine Residency | Chiangmai University, Chiangmai, Thailand |
| 2001-2002 | Medical Oncology Fellowship | Chiangmai University, Chiangmai, Thailand |

Certification

Thai Board of Internal Medicine

Thai Board of Medical Oncology

Professional Affiliation

Member of The Medical Council of Thailand

Member of The Royal College of Physicians of Thailand

Member of The Thai Society of Clinical Oncology

Publications

1. Thongprasert S., Cheewakriangkrai R., Napapan S. Docetaxel as second-line Chemotherapy for advanced non-small cell lung cancer. J Med Assoc Thai. 2002 Dec;85(12):1296-300
2. Thongprasert S., Napapan S., Charoentum C. et al Phase II study of gemcitabine plus cisplatin in biliary tract cancer. Proc Am Soc Clin Oncol 2003;22;1221
3. Sorrarittichingchai S., Thongprasert S., Charoentum C. et al Treatment of advanced non-small cell lung cancer with vinorelbine in elderly Thai patients. J Med Assoc Thai. 2004 Apr;87(4):367-71
4. Thongprasert S., Napapan S., Charoentum C. et al Phase II study of gemcitabine and cisplatin as first-line chemotherapy in inoperable biliary tract carcinoma. Ann Oncol 2005 Feb;16(2):279-81

5. Thongprasert S., Soorarithchingchai S., Chewasakulyong B. et al A Phase II study of Docetaxel and Carboplatin in Thai Patients with advanced non-small cell lung cancer. J Med Assoc Thai. 2006 Apr;89(2):152-9

Clinical Trial Participation

1. A Phase III, Randomised, Double-Blind, Multi-Centre Parallel – Group Study to Assess The Efficacy of ZD6474(ZACTIMATM) Versus Erlotinib(TARCEVATM) in Patients With Locally Advanced or Metastatic (stage IIIB-IV) Non-Small Cell Lung Cancer(NSCLC) after Failure of at least One Prior Cytotoxic Chemotherapy.
2. Active implementation of Quality of Life (QOL) assessment in clinical practice for patients with advanced NSCLC and comparison of QOL and response endpoints / AP QOL Leadership.
3. A Randomised, Multicenter, Phase III Study Comparing the Combination of Pazopanib and Lapatinib Monotherapy in Patients with ErbB2 over-expressing Inflammatory Breast Cancer.
4. Observational Study Protocol: Breast Cancer Registry of Adjuvant Strategies_Thailand
5. Registry of Colorectal Cancer Disease Treatment-Metastasis
6. A Randomised, double-blind and placebo controlled multicentre study comparing BP-C1 and equal looking placebo in metastatic breast cancer patients. A phase IIB study.
7. Estimation of the optimal treatment duration and cumulative dose of BP-C1 in breast cancer patients with distant metastases: A dose- response study (IC)
8. A multicenter, randomized, double-blind Phase III trial to evaluate efficacy and safety of BI 695502 plus chemotherapy versus Avastin® plus chemotherapy in patients with advanced nonsquamous Non-Small Cell Lung Cancer” Protocol No. 1302.5 (enrolment completed)
9. A Phase III, open-label, multicentre, randomised trial to establish safety and efficacy of an EGF cancer vaccine in inoperable, stage IV biomarker positive, wild type EGF-R NSCLC patients eligible to receive standard treatment and supportive care (on going)